The disclosure is in the field of immunology and provides means and methods for the treatment of multiple sclerosis. More in particular, the disclosure relates to means and methods for inducing immune tolerance to an antigen, wherein the antigen is covalently attached to a sialylated oligosaccharide, in particular, 6′-sialyl-N-acetyllactosamine. More in particular, the disclosure provides means and methods for inducing immune tolerance against an antigen derived from myelin, such as a myelin component, such as myelin oligodendrocyte glycoprotein, a well-known target in experimental autoimmune encephalomyelitis, a murine multiple sclerosis model.
